Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGS-v PLUS in healthy volunteers
NCT04009824Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2019
- Primary completion
- Mar 2020
- Modality
- Antisense DNA, Vaccines & Immunotherapeutics, Small Interfering RNA (siRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AGS-v PLUS in mosquito-borne infectious diseases (5 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Incidence of Severity of Treatment Emergent Adverse Events at 1 year, Mean log10 Titer in Serum AGS-v PLUS Specific Immunoglobulin Titers at Day 43 and 3 more. Started Jul 2019; status: completed.
02
Drugs
AGS-v PLUS
03
Conditions
mosquito-borne infectious diseases
Beyond the preview
Go deeper on NCT04009824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04009824.